Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 136 projects in pharma, of which 37 are active.
20 new construction, 16 expansion, and 1 revamp / retrofit.
3 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (4), Lilly (3), Merck (3), Novo Nordisk (3), Eli Lilly and Company (2), Genentech, Inc. (2)
Investors: Eli Lilly and Company (2), European Investment Bank (2), Evonik Industries AG (2), Takeda (2), AGC Group (1), Clariant AG (1)
Contractors, licensors, and offtakers are recorded on 13 of these 37 projects For subscribers
Targeting: Orforglipron (5), Retatrutide (2), Coagulation factor IX (1), Fumed Silica (1), Glucagon-like peptide-1 (1), Isobutene (1)
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
Oral ICOTYDE maintains durable skin clearance through Week 112 and yields high site‑specific clearance rates for scalp, genital, hand/foot and nails.
FDA clears pirtobrutinib for newly diagnosed CLL/SLL patients without 17p deletion after BRUIN CLL-313 showed a large PFS benefit versus bendamustine–rituximab.
FDA review remains ongoing; extension caused by facility remediation, not clinical deficiencies. Novo still targets a US launch in H1 2027 and says 2026 outlook is unaffected.
2.2 billion USD project in New Albany will add ~600 permanent roles and ~1,500 construction jobs; first drug substance module operational in 2031, drug product in 2034.
Mid‑year operational results, NPL implementation progress, CTIS upgrade tied to the Biotech Act, and arrangements for the next Executive Director.
Workshop to close gaps in research, diagnosis and treatment for women; aims to deliver a practical roadmap and public report to speed innovation and improve outcomes.
MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
By country, the most active first. active / all projects
The 8 with the most active projects, of 26 countries.
